The PRIME study: Classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland

QJM: An International Journal of Medicine

Volumn 91, Issue 10, 1998, Pages 667-676

  Yarnell, J W G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; FIBRINOGEN; TRIACYLGLYCEROL;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; DEMOGRAPHY; FOLLOW UP; FRANCE; HEART INFARCTION; HEREDITY; HUMAN; HUMAN CELL; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; STATISTICS; UNITED KINGDOM;

EID: 0031726749     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialised countries since 1950. Wld Hlth Statist Quart 1988; 41:155-78.
2. WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (MONItoring trends and determinants in CArdiovascular disease): A major international collaboration. J Clin Epidemiol 1988; 41:105-14.
3. The WHO MONICA Project. Geographical variations in the major risk factors of coronary heart disease in men and women aged 35-64 years. Wld Hlth Stat Quart 1988; 41:115-36.
4. Tunstall-Pedoe H, et al. On behalf of WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Circulation 1994; 90:583-612.
5. Parra HJ, Arveiler D, Evans AE, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for CHD, the ECTIM Study. Arterioscler Thromb 1992; 12:701-7.
6. Moreel JFR, Roizes G, Evans AE, et al. The polymorphism Apo B/4311 in patients with MI and controls: the ECTIM Study. Hum Genet 1992; 89:169-75.
7. Luc G, Bard JM, Arveiler D, et al. The impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM study. Arterioscler Thromb 1994; 14:1412-19.
8. Scarabin PY, Barra L, Ricard S, et al. Genetic variation at the b fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. Arterioscler Thromb 1993; 13:886-91.
9. Cambien F, Poirier O, Lecerf L, ef al. Deletion polymorphism at the angiotensin-converting enzyme gene is a potent risk factor for myocardial infarction. Nature 1992; 359:641-4.
10. Feinstein AR, Methodologic problems and standards in case-control research. J Chron Dis 1979; 32:35-41.
11. Donohue RP, Abbort RD, Bloom E, et al. Central obesity and coronary heart disease in men. Lancet 1987; 1:822-4.
12. Evans AE, Ruidavets J-B, McCrum EE, et al. Autres pays, autres coeurs? Dietary patterns, risk factors and ischaemic heart disease in Belfast and Toulouse. Q J Med 1995; 88:469-77.
13. Jost JP, Simon C, Nuttens MC, et al. Comparison of dietary patterns between population samples in the three French MONICA nutritional surveys. Rev Epidemiol Sant Publ 1990; 38:517-23.
14. Tiret L, Kee F, Poirier O, et al. Deletion polymorphism in the angiotensin converting enzyme gene is associated with a parental history of myocardial infarction. Lancet 1993; 341:991-2.
15. Evans AE, Poirier O, Kee F, et al. Polymorphisms of the angiotensin-converting gene in subjects who die from coronary heart disease. Q J Med 1994; 87:211-14.
16. Kee F, Tiret L, Robo JY et al. Reliability of reported family history of myocardial infarction. Br Med J 1993; 307:1528-30.
17. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods, 2nd edn. Geneva, WHO, 1982.
18. Fruchart JC, Kandoussi A, Parsy D, Koren E, Puchois P. Measurement of lipoprotein particles defined by their apolipoprotein composition using immunosorbent assay. In: Annual meeting on clinical chemistry, Mannheim 25-28 September 1985 (Abstr). J Clin Chem Clin Biochem 1985; 23:619.
19. Fruchart JC, Fievet C, Puchois P. In Bergmayer, ed. Methods of enzymatic analysis; apolipoproteins. Weinheim, FRG Verlag Chemie, 1985:126-38.
20. Theret N, Bard JM, Nuttens MC, et al. The relationship between the phospholipid fatty acid composition of red blood cells and plasma lipids and apolipoproteins. Metabolism 1993; 42:562-8.
21. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17:237-47.
22. Brozovic M, Stirling Y, Harricks C, North WRS, Meade TW. Factor VII in an industrial population. Br J Haematol 1974; 28:381-91.
23. Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31:427-36.
24. Mazzucconi MG, Mandelli F, Mariani G, Briete E, Veltkamp JJ. A CRM-positive variant of factor VII deficiency and the detection of heterozygotes with the assay of factor-like antigen. Br J Haematol 1977; 36:127-35.
25. Declerk PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71:220-5.
26. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54:684-7.
27. Bartlett A, Dormandy KM, Hawkey CM, Stableforth P, Voller A. Factor VIII related antigen: measurement by enzyme immunoassay. Br Med J 1976; 1:994-6.
28. Soria J, Soria C, Boucheix C, et al. Monoclonal antibodies that react preferentially with fibrinogen degradation products or with crosslinked fibrin split products. Ann New York Acad Sci 1983; 408:665-6.
29. Wilson MA, Miles LE. Radioimmunoassay of insulin. In: Abraham GE, ed. Handbook of Radioimmunoassay. New York, Dekker, 1977:275.
30. Jurgens H, Pratt JJ, Woldring MG. Radioimmunoassay of plasma estradiol without extraction and chromatography. J Clin Endocrinol Metab 1975; 40:19-25.
31. Rattcliffe WA. Direct serum assays for steroids. In: Hunter WM, Corrie JET, eds. Immunoassays for Clinical Chemistry. Edinburgh, Churchill Livingstone, 1983:401.
32. Marquès-Vidal P, Sié P, Cambou JP, Chap H, Perret B. Relationships of plasminogen activator inhibitor activity and Lipoprotein(a) with Insulin, Testosterone, 17β-Estradiol, and Testosterone Binding Globulin in myocardial infarction patients and healthy controls. J Clin Endocrinol Metab 1995; 80:1794.
33. Miles LEM. Immunoradiometric assay and two-site IRMA systems. In: Abraham GE, ed. Handbook of Radioimmunoassay. New York, Dekker, 1977:131-77.
34. Hess D, Keller KE, Oberlin B, Bonfanti R, Schuep W. Simultaneous determination of retinol, tocopherols, carotenes and lycopene in plasma by means of high-performance liquid chromatography on reversed phase. Int J Vitam Nutr Res 1992; 61:232-8.
35. Jordan P, Brubacher D, Moser U, Stähelin HB, Gey KF. Vitamin E and vitamin A concentrations in plasma adjusted for cholesterol and triglycerides by multiple regression. Clin Chem 1995; 41:924-7.
36. Brubacher G, Vuilleumier JP. Procedure for the determination of vitamin C in plasma. In: Curtius HC, Roth M eds. Clinical Biochemistry Principles and Methods. Berlin, de Gruyter, 1974:992-7.
37. McMaster D, Anderson P, Bell N, Love AHG. Automated measurement of two indicators of human selenium status, and applicability to population studies. Clin Chem 1990; 36:211-16.
38. McMaster D, McCrum E, Patterson CC, et al. Serum copper and zinc in random samples of the population of Northern Ireland. Am J Clin Nutr 1992; 56:440-6.
39. Alaupovic P. Conceptual development of the classification system of plasma lipoproteins. Protides Biol Fluids Proc Colloq 1972; 19:9-19.
40. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246:904-10.
41. Utermann G, Kraft HG, Menzel HJ, Hopferwieser T, Seitz C. Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of Lp(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma. Hum Genet 1988; 78:41-6.
42. Utermann G, Duba C, Menzel HJ. Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes. Hum Genet 1988; 78:47-50.
43. Meade TW, North WRS, Chakrabarti R, et al. Haemostatic function and cardiovascular death: Early results of a prospective study. Lancet, 1980; i:1050-4.
44. Meade TW, Brozovic M, Chakrabarti R, et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet, 1986; ii:533-7.
45. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-9.
46. Wilhemsen L, Swardsudd K, Korsan-Bengsten K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311:501-5.
47. Stone MC, Thorpe JM. Plasma fibrinogen - a major coronary risk factor. J Roy Coll Gen Pract 1985; 118:956-63.
48. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258:1183-6.
49. Barker DJP. Fetal origins of coronary heart disease. Br Med J 1995; 315:171-4.
50. Marques-Vidal P, Evans AE, Cambou J-P, et al. Awareness and control of hypertension and hyercholesterolaemia in France and Northern Ireland. Q J Med 1997; 90:341-5.
51. Ducimetière P, Richard JL, Cambien F, Rakotovao R, Claude JR. Coronary heart disease in middle-aged Frenchmen: comparisons between the Paris Prospective Study, Seven Countries Study, and Pooling Project. Lancet 1980; 1:1346-50.